Currently, the diagnosis of molecular subtypes of breast tumor is mainly based on surgical or puncture biopsy immunohistochemistry, which is the gold standard for the detection of ER, PR, HER-2, and Ki-67 expression, and the reliability of its tests also depends on the handling of the tissue, which may sometimes lead to false positives and false negatives [15]. Here, ERBB2 is linked to breast neoplasm.